Special Educational Needs: support in England
An overview of the current system of support for children and young people with special educational needs, and pressure on the system
This briefing provides an overview on the Independent Medicines and Medical Devices Safety review, its findings, and the Government action in response to its recommendations.
The Independent Medicines and Medical Devices Review (6 MB , PDF)
The Independent Medicines and Medical Devices Safety review was announced by the former Secretary of State for Health and Social Care, Jeremy Hunt, in February 2018 to look at three issues of concern:
Following the consideration of written and oral evidence from patients and their families, campaigners, healthcare professionals and regulators over a two-year period, the review published the report of its findings and recommendations, First do no harm, in July 2020.
There were nine recommendations. These included the establishment of an independent Patient Safety Commissioner, the introduction of redress schemes for those affected by these products, and changes to the way the medicines regulator, the Medicines and Healthcare products Regulatory Agency, works with patients.
In its full response to the review in July 2021, the Government said that it “fully accepts the overarching conclusion that the system failed to listen to patients, or to put patients at the centre of their care.”
The Government accepted recommendations on the establishment of a new Patient Safety Commissioner role, specialist centres for the care of those with complications from mesh implants, and changes to how conflicts of interests for doctors are reported. It did not accept the recommendation on the setting up of an independent redress agency for those harmed by mesh implants, and medicines in pregnancy.
This briefing provides an overview of the Independent Medicines and Medical Devices Review and its recommendations, and the Government’s response to this.
The Independent Medicines and Medical Devices Review (6 MB , PDF)
An overview of the current system of support for children and young people with special educational needs, and pressure on the system
A briefing on the licensing, regulation and supply of new weight loss medications in England.
A debate has been scheduled in Westminster Hall for 3pm on 23 January on innovation in the field of rare retinal disease. The subject for the debate has been chosen by the Backbench Business Committee, and the debate will be opened by Jim Shannon MP.